Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORETHIN 1/50M-21 vs ESTROSTEP FE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norethindrone is a progestin that suppresses gonadotropin release from the pituitary, inhibiting ovulation. It also induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.
Treatment of endometriosis,Treatment of abnormal uterine bleeding,Contraception,Amenorrhea,Palliative treatment of advanced breast cancer (off-label)
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no known contraindications, who have achieved menarche)
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).
Terminal elimination half-life: 5-14 hours (mean ~8h). Clinical context: Steady-state achieved after 4-5 days; dosing interval 24 hours maintains therapeutic levels.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours. Clinical context: Steady-state reached within 7-10 days.
Hepatic metabolism primarily via reduction and conjugation; minor CYP3A4 involvement. Metabolites are excreted in urine and feces.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Norethindrone acetate: hydrolyzed to norethindrone, then metabolized by reduction and glucuronidation.
Renal: 50-60% as metabolites; Fecal: 30-40% (via biliary); Less than 5% unchanged in urine.
Renal: ~40% as metabolites; fecal: ~30% (biliary); remainder as conjugates.
97-98% bound; primarily to albumin (70%) and SHBG (30%).
Ethinyl estradiol: 97-98% bound to albumin and SHBG; norethindrone acetate: 91-95% bound to albumin and SHBG.
3.6-4.7 L/kg; indicates extensive tissue distribution, including breast tissue and adipose.
Ethinyl estradiol: 2.3-3.6 L/kg; norethindrone acetate: 1.5-2.5 L/kg. Indicates extensive tissue distribution.
Oral: 64-76% (first-pass metabolism reduces bioavailability).
Oral: Ethinyl estradiol ~45% (first-pass metabolism); norethindrone acetate ~64%.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention.
No dose adjustment is recommended for patients with mild to moderate renal impairment. Use is contraindicated in patients with severely impaired renal function (GFR <30 m L/min/1.73 m²) due to potential for fluid retention and hyperkalemia.
Contraindicated in hepatic impairment, including active liver disease, jaundice, or Child-Pugh class B or C. No studies for mild impairment; use not recommended.
Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), use with caution and monitor liver function; no specific dose adjustment guidelines are established.
Not indicated for use before menarche. Post-menarche, use same dosing as adults (one tablet daily) with monitoring for thromboembolic risks.
Safety and efficacy have not been established in pediatric patients below 16 years of age. Post-pubertal adolescents may be dosed as adults, with careful consideration of risks (e.g., bone density).
Not indicated for postmenopausal women. In older reproductive-age women, use same adult dosing; monitor for cardiovascular and thromboembolic risks due to higher estrogen dose.
Not indicated for use in women over 65 years due to lack of efficacy and safety data, and increased risk of cardiovascular and thrombotic events.
Cigarette smoking increases the risk of serious cardiovascular side effects from combined oral contraceptives. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is marked in women over 35 years who smoke. Combined oral contraceptives should not be used by women over 35 years who smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking intensity (especially >35 years). Women >35 years who smoke should not use this product.
Increased risk of thromboembolic disorders, especially in smokers over 35. Hepatotoxicity risk. May cause fluid retention. Monitor for depression, elevated blood pressure, and glucose intolerance. Discontinue if jaundice or visual disturbances occur.
Thromboembolic disorders, cardiovascular disease (MI, stroke), hypertension, gallbladder disease, hepatic neoplasia, lipid effects, glucose intolerance, headache, breakthrough bleeding, depression, contact lens intolerance, fluid retention, hereditary angioedema.
Known or suspected pregnancy, history of or current thrombophlebitis or thromboembolic disorders, cerebrovascular disease, coronary artery disease, hepatic impairment or liver tumors, undiagnosed abnormal uterine bleeding, known or suspected breast carcinoma (unless for palliation), hypersensitivity to norethindrone.
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast carcinoma, endometrial carcinoma or other estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior pill use, hepatic adenoma or carcinoma, pregnancy, hypersensitivity to any component.
No significant food interactions. However, maintaining a consistent diet is recommended to avoid gastrointestinal upset. Grapefruit juice may inhibit CYP3A4 and increase estrogen levels, but clinical significance is low.
No specific food interactions are reported for Estrostep Fe. Grapefruit juice may slightly increase estrogen levels but is not considered clinically significant. There are no dietary restrictions. However, patients should maintain a consistent intake of folic acid if planning pregnancy; iron supplements can be taken with food to reduce GI upset.
Contraindicated in pregnancy. First trimester: Association with cardiovascular defects and limb reduction defects (case-control studies show odds ratio 1.3-2.8 for oral contraceptive use). Second and third trimesters: No increased risk of major malformations if inadvertently exposed; however, hormones can affect fetal endocrine development. Use is not recommended during any trimester.
Category X. Estrostep FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects from sex hormones. Second/third trimester: feminization of male fetus, potential for urogenital malformations, and long-term reproductive tract effects. Postnatal: possible increased risk of childhood cancers.
Excreted in breast milk in small amounts (estrogen and progestin). M/P ratio not established for this fixed-dose combination. May reduce milk production and composition, especially in early postpartum. American Academy of Pediatrics considers use compatible with breastfeeding, but alternative contraception recommended. Monitor infant for jaundice and weight gain.
Excreted in breast milk in small amounts (estrogen M/P ratio ~0.2, progestin M/P ratio ~0.6). May reduce milk quantity and quality. Use caution; generally not recommended. No adverse effects reported in infants at typical doses.
Contraindicated in pregnancy; no dose adjustment applicable. If used inadvertently, discontinue immediately. No pharmacokinetic studies in pregnancy due to contraindication. Theoretical decreased contraceptive efficacy during pregnancy is irrelevant.
Contraindicated; no dose adjustment needed because drug should be discontinued immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) not applicable due to contraindication.
Monitor for thromboembolic events, especially in smokers over 35. Advise use of barrier contraception to reduce STI risk. Assess blood pressure at baseline and follow-up due to potential estrogenic effects. May reduce menstrual flow and dysmenorrhea.
Estrostep Fe is a combined oral contraceptive containing norethindrone acetate and ethinyl estradiol. It is unique among OCPs for its step-up estrogen regimen (20, 30, 35 mcg EE) intended to mimic natural menstrual cycle. Clinicians should note that it is not FDA-approved for acne treatment, though it is often used off-label; only Estrostep (non-Fe) is approved for acne. The iron (ferrous fumarate) in the last 7 tablets is a placebo. It is a low-dose pill; missed doses more likely cause breakthrough bleeding. Contraindications include smoking >35, history of DVT/PE, migraine with aura, liver disease, breast cancer. Counsel patients to take at same time daily; if missed, follow standard missed pill protocol.
Take one tablet daily at the same time, even if you do not have sex.,If you miss a pill, follow the package instructions or consult your healthcare provider.,Smoking while taking this pill increases risk of blood clots, especially if over age 35.,This pill does not protect against HIV or other sexually transmitted infections.,Contact your doctor if you experience severe headaches, vision changes, or leg pain/swelling.
Take one pill at the same time each day. The first 21 pills contain active hormones; the last 7 pills are iron tablets (not hormones).,If you miss a pill, refer to the package insert or contact your healthcare provider. Use backup contraception (condoms) if pills are missed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Estrostep Fe does not protect against sexually transmitted infections (STIs). Always use condoms for STI prevention.,Smoking while using this pill increases risk of serious cardiovascular events. Do not smoke.,Contact your doctor if you experience signs of a blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,The iron in the last 7 pills is to help with iron levels but does not provide hormonal contraception during that week.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORETHIN 1/50M-21 vs ESTROSTEP FE, answered by our medical review team.
NORETHIN 1/50M-21 is a Combined Oral Contraceptive that works by Norethindrone is a progestin that suppresses gonadotropin release from the pituitary, inhibiting ovulation. It also induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.. ESTROSTEP FE is a Combined Oral Contraceptive that works by Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORETHIN 1/50M-21 and ESTROSTEP FE depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORETHIN 1/50M-21 is: One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of ESTROSTEP FE is: One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORETHIN 1/50M-21 and ESTROSTEP FE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORETHIN 1/50M-21 is classified as Category C. Contraindicated in pregnancy. First trimester: Association with cardiovascular defects and limb reduction defects (case-control studies show odds ratio 1.3-2.8 for oral contracepti. ESTROSTEP FE is classified as Category C. Category X. Estrostep FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiov. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.